1. 23年开始医保报销金额大涨：HIFU Reimbursement 90% Increase to APC 6；Endometriosis Phase 3 Double-blind RCT Enrollment Completion；4季度销售额不错。
2. 新适应症拓展：Endometriosis Phase 3 Double-blind RCT Enrollment Completion，Results expected second half of 2024；前面2期数据很好。近期获得FDA Breakthrough Device Designation
3. Cash Position of $50.5 Million as of September 30, 2023；市值2.87亿。重点在于接下来各季度的销售额 以及下半三期结果。